These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7620695)

  • 1. Clinical evaluation of bevantolol hydrochloride in patients with severe hypertension. The Cooperative Study Group on Bevantolol in Japan.
    Noshiro T; Miura Y; Yoshinaga K; Iimura O; Inagaki Y; Saruta T; Ishii M; Yamazaki N; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):240-5. PubMed ID: 7620695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The blood pressure responses of thiazide-resistant hypertensives to a once-a-day bevantolol regimen.
    Snedden W; Fernandez PG; Nath C
    Can J Cardiol; 1987 Oct; 3(7):322-5. PubMed ID: 2892582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension.
    Sasaki J; Kajiyama G; Kusukawa R; Mori H; Koga S; Takagi R; Tanaka N; Ogawa N; Arakawa K
    Int J Clin Pharmacol Ther; 1994 Dec; 32(12):660-4. PubMed ID: 7881705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of hydrochlorothiazide and hydrochlorothiazide plus bevantolol in hypertension.
    Lucas CP; Morledge JH; Tessman DK
    Clin Ther; 1985; 8(1):49-60. PubMed ID: 2870810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nebivolol, a third generation beta blocker: the modern treatment of hypertension. Results of a multicentric observational study].
    von Fallois J; Faülhaber HD
    Fortschr Med Orig; 2000 Jul; 118 Suppl 2():77-82. PubMed ID: 15700490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose response studies of bevantolol in hypertensive patients.
    Okawa KK
    Angiology; 1986 Mar; 37(3 Pt 2):233-8. PubMed ID: 2871783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevantolol vs propranolol: a double-blind controlled trial in essential hypertension.
    Maclean D
    Angiology; 1988 Jun; 39(6):487-96. PubMed ID: 2897812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial.
    Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR
    J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH; Kim YD; Lim DS; Yoon MH; Ahn YK; On YK; Lee JW; Kim IJ; Park JB; Kim JJ; Chung WS; Yang JY; Seo HS; Shin EK; Kim HS;
    Clin Ther; 2007 Sep; 29(9):1924-36. PubMed ID: 18035192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of treatment effects of bevantolol and metoprolol on cardiac function and natriuretic peptides in patients with dilated cardiomyopathy.
    Hara Y; Hamada M; Ohtsuka T; Ogimoto A; Saeki H; Matsunaka T; Suzuki J; Shigematsu Y
    Heart Vessels; 2002 Dec; 17(2):53-6. PubMed ID: 12541094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age dependence of therapy result and risk in the treatment of arterial hypertension?
    Höffler D; Morgenstern HO
    J Cardiovasc Pharmacol; 1990; 16 Suppl 5():S184-8. PubMed ID: 11527125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevantolol attenuates thiazide stimulated renin secretion and catecholamine release in diuretic resistant hypertensives.
    Fernandez PG; Snedden W; Vasdev S; Bolli P
    Can J Cardiol; 1989 Mar; 5(2):93-7. PubMed ID: 2565158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and tolerability of tertatolol in the treatment of mild to moderate arterial hypertension. Results of a French multicenter study with 2,338 patients treated over one year].
    Herpin D; Piron J; Bajou B; Lecasble M
    Ann Cardiol Angeiol (Paris); 1989 Oct; 38(8):503-7. PubMed ID: 2574560
    [No Abstract]   [Full Text] [Related]  

  • 16. [Field study: long-term antihypertensive therapy with the beta blocker nadolol in a once-a-day dosage - an outpatient study of Swiss medical practices].
    Bertel O; Conen D; Renggli I
    Schweiz Rundsch Med Prax; 1983 Feb; 72(8):264-8. PubMed ID: 6132374
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of bevantolol and atenolol for systemic hypertension.
    Fairhurst GJ
    Am J Cardiol; 1986 Nov; 58(12):25E-27E. PubMed ID: 2878597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metoprolol, a new cardioselective beta blocking agent in the treatment of arterial hypertension].
    Pedersen OL
    Ugeskr Laeger; 1975 Sep; 137(39):2274-6. PubMed ID: 241148
    [No Abstract]   [Full Text] [Related]  

  • 19. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial.
    Minutolo R; Gabbai FB; Borrelli S; Scigliano R; Trucillo P; Baldanza D; Laurino S; Mascia S; Conte G; De Nicola L
    Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects.
    O'Shaughnessy KM; Fu B; Dickerson C; Thurston D; Brown MJ
    Clin Sci (Lond); 2000 Sep; 99(3):233-8. PubMed ID: 11787477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.